Cost-Effective Innovation

November 12, 2015
Tim Mayleben
President and Chief Executive Officer

By now you’ve read the headlines about the high cost of the new cholesterol lowering drugs.  We’ve been bombarded with commentary, articles and opinion pieces on these drugs and their high prices.  The PCSK9 inhibitors – injectable, biologic drugs that dramatically lower LDL-cholesterol – appear to be very efficacious.  But these drugs are priced at… Read More

NLA 2014 Scientific Sessions: Placing the Focus on Statin Intolerance

May 19, 2014
Roger Newton, PhD, FAHA
Executive Chairman and Chief Scientific Officer
Marianne Andreach
Vice President, Strategic Marketing & Product Planning

As members of the Esperion team developing ETC-1002—a unique, first-in-class, orally available, once-daily small molecule designed to lower low density lipoprotein cholesterol (LDL-C) levels, particularly in individuals with hypercholesterolemia who are intolerant to statins—we are excited any time there is a specific emphasis on, or a new development in, this underserved patient population. In the… Read More

ACC.14: Spotlighting the Importance of Finding New Therapies for Statin Intolerant Patients

April 21, 2014
Roger Newton, PhD, FAHA
Executive Chairman and Chief Scientific Officer

Late last month, the American College of Cardiology (ACC) held its 63rd Annual Scientific Session & Expo with more than 13,000 cardiovascular experts coming together in Washington, D.C. As I have for many years, I traveled to ACC.14 with my Esperion colleagues to hear firsthand the latest research findings in the prevention, diagnosis and treatment… Read More

A Conversation with Dr. Robert Eckel About Treating Patients with Both Diabetes and Hypercholesterolemia

March 28, 2014
Robert H. Eckel, MD
Professor of Medicine and holds the Charles A. Boettcher Endowed Chair in Atherosclerosis at the University of Colorado School of Medicine

In March 2014, Arteriosclerosis, Thrombosis, and Vascular Biology, a journal of the American Heart Association, published the results of ETC-1002-005, Esperion’s Phase 2a clinical study of ETC-1002 in patients with hypercholesterolemia and type 2 diabetes, along with an editorial about targeting low-density lipoprotein cholesterol (LDL-C) and diabetes in those patients. ETC-1002-005 was a randomized, double-blind,… Read More

Looking Back on a Successful 2013 and a Glance Ahead at a Promising 2014

December 31, 2013
Tim Mayleben
President and Chief Executive Officer

Esperion had an incredible year in 2013 with more successes, both clinically and financially, than in any other year since we were founded in April 2008 as the new Esperion. We executed on all of our milestones – all toward our goal of bringing ETC-1002 to market. A unique, first-in-class, oral, once-daily investigational small molecule,… Read More

Posted In: Company News

The Promise of ETC-1002 for Patients at Risk of Cardiovascular Disease

October 15, 2013
Noah Rosenberg
Chief Medical Officer

Many years ago, as an attending physician in an academic emergency department, I was surprised to see a number of patients presenting with advanced cardiovascular disease (CVD). What made this so unusual was that these patients had no known “traditional” CVD risk factors, such as smoking or high blood pressure, but were all relatively young–in… Read More

Posted In: Company News